Opponents continue to protest -- most recently at a U.S. House subcommittee hearing -- that the merger of two of the three largest pharmacy-benefits managers would reduce consumer choice, increase costs and decrease overall satisfaction. The outlook for approval looks positive, however.
By James Lawson
Opposition continues to mount against the proposed $21-billion merger between two of the thre